Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-07
2011-06-07
Belyavskyi, Michail A (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S391100
Reexamination Certificate
active
07956164
ABSTRACT:
T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities.
REFERENCES:
patent: 4279249 (1981-07-01), Vert et al.
patent: 5126132 (1992-06-01), Rosenberg
patent: 5443983 (1995-08-01), Ochoa et al.
patent: 5766920 (1998-06-01), Babbitt et al.
patent: 5806529 (1998-09-01), Reisner et al.
patent: 5846827 (1998-12-01), Celis et al.
patent: 6040177 (2000-03-01), Riddell et al.
patent: 6194207 (2001-02-01), Bell et al.
patent: 6251385 (2001-06-01), Terman
patent: 6255073 (2001-07-01), Cai et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6500193 (2002-12-01), Bezemer et al.
patent: 6511511 (2003-01-01), Slivka et al.
patent: 6514286 (2003-02-01), Leatherbury et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6572894 (2003-06-01), Rossling et al.
patent: 6867041 (2005-03-01), Berenson et al.
patent: 6887466 (2005-05-01), June et al.
patent: 6905680 (2005-06-01), June et al.
patent: 6905681 (2005-06-01), June et al.
patent: 6905874 (2005-06-01), Berenson et al.
patent: 7402431 (2008-07-01), Har-Noy
patent: 7435592 (2008-10-01), Har-Noy
patent: 7592431 (2009-09-01), Har-Noy
patent: 7678572 (2010-03-01), Har-Noy
patent: 2002/0127208 (2002-09-01), Waller et al.
patent: 2003/0004578 (2003-01-01), Brown et al.
patent: 2003/0175272 (2003-09-01), Gruenberg
patent: 2003/0215946 (2003-11-01), Nair et al.
patent: 2005/0065593 (2005-03-01), Chu et al.
patent: 2005/0191746 (2005-09-01), Van et al.
patent: 2006/0036331 (2006-02-01), Lu et al.
patent: 2006/0121021 (2006-06-01), Hunig
patent: 2007/0086996 (2007-04-01), Har-Noy
patent: 0319012 (1989-06-01), None
patent: 9412196 (1994-06-01), None
patent: 9746256 (1997-12-01), None
patent: 9924045 (1999-05-01), None
patent: 0162895 (2001-08-01), None
patent: 03024989 (2003-03-01), None
patent: 03/038062 (2003-05-01), None
patent: 2004004768 (2004-01-01), None
patent: 2005001074 (2005-01-01), None
patent: 2005081982 (2005-09-01), None
patent: 2005084276 (2005-09-01), None
Antin, J. H. et al. (1992). “Cytokine Dysregulation and Acute Graft-Versus-Host Disease.” Blood, vol. 80, No. 12: pp. 2964-2968.
Anderson, P. et al. (1988). “Crosslinking CD3 with CD2 Using Sepharose-Immobilized Antibodies Enhances T Lymphocyte Proliferation.” Cellular Immunology, vol. 115, No. 2: pp. 246-256.
Asselin-Paturel et al. (1998). “Quantitative Analysis of Th1, Th2 and TGF-β1 Cytokine Expression in Tumor, TIL and PBL of Non-Small Cell Lung Cancer Patients.” Int. J. Cancer, vol. 77, No. 1: pp. 7-12.
Bachmann, M. F. et al. (1997). “Distinct Roles for LFA-1 and CD28 During Activation of Naive T Cells: Adhesion Versus Costimulation.” Immunity, vol. 7, No. 4: pp. 549-557.
Banu, N. et al. (1999). “TGF-β1 down-regulates induced expression of both class II MHC and B7-1 on primary murine renal tubular epithelial cells.” Kidney International, vol. 56, No. 3: pp. 985-994.
Baroja, M.L. et al. (1989). “The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cell Activation with Immobilized Anti-CD3 and Mitogens.” Cellular Immunology, vol. 120, No. 1: pp. 205-217.
Baxevanis, C. N. et al. (2000). “Compromised anti-tumor responses in tumor necrosis factor-α knockout mice.” Eur. J. Immunol, vol. 30, No. 7: pp. 1957-1966.
Belardelli, F. et al. (2002). “Cytokines as a link between innate and adaptive antitumor immunity.” Trends in Immunology, vol. 23 No. 4: pp. 201-208.
Blazar, B. R. et al. (1997). “Recent advances in graft-versus-host disease (GVHD) prevention.” Immunological Reviews, vol. 157: pp. 79-109.
Blazar, B. R. et al. (1998). “Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus-Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines.” Journal of Immunology, vol. 160, No. 11: pp. 5355-5365.
Carayol, G. et al. (1997). “Quantitative Analysis of T Helper 1, T Helper 2, and Inflammatory Cytokine Expression in Patients After Allogeneic Bone Narrow Transplantation: Relationship with the Occurrence of Acute Graft-Versus-Host Disease.” Transplantation, vol. 63, No. 9: pp. 1307-1313.
Carpentier, A. F., G. Auf, et al (2003). “CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.” Front Biosci 8: E115-27.
Chambers, C. A. et al. (1999). “Costimulatory regulation of T cell function.” Current Opinion in Cell Biology, vol. 11, No. 2: pp. 203-210.
Champlin, R., I. Khouri, et al. (1999). “Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.” Hematol Oncol Clin North Am 13(5): 1041-57, vii-viii.
Champlin, R., K. van Besien, et al. (2000). “Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens.” Curr Oncol Rep 2(2): 182-91.
Chang, J. W., M. Peng, et al. (2000). “Induction of Th1 response by dendritic cells pulsed with autologous melanoma apoptotic bodies.” Anticancer Res 20(3A): 1329-36.
Chen, Q. et al. (1994). “Production of IL-10 by Melanoma Cells: Examination of its Role in Immunosuppression Mediated by Melanoma.” Int. J. Cancer, vol. 56, No. 5: pp. 755-760.
Childs, R. et al. (2002). “Nonmyeloablative Stem Cell Transplantation for Solid Tumors: Expanding the Application of Allogeneic Immunotherapy.” Seminars in Hematology, vol. 39, No. 1: pp. 63-71.
Childs, R. et al. (2000). “Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.” The New England Journal of Medicine, vol. 343, No. 11: pp. 750-758.
Childs, R. W. (2000). “Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases.” Cancer J 6(3): 179-87.
Childs, R. W. (2002). “Immunotherapy of solid tumors: nonmyeloablative allogeneic stem cell transplantation.” MedGenMed 4(3): 13.
Cierici, M. et al. (1993). “A TH1→TH2 switch is a critical step in the etiology of HIV infection.” Immunology Today, vol. 14, No. 3: pp. 107-111.
Cohen, P. A., L. Peng, et al. (2000). “CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.” Crit Rev Immunol 20(1): 17-56.
Damle, N.K. et al. (1989). “Stimulation Via the CD3 and CD28 Molecules Induces Responsiveness to IL-4 in CD4+CD29+CD45R-Memory T Lymphocytes.” The Journal of Immunology, vol. 143, No. 6: pp. 1761-1767.
Das, H., S. Imoto, et al. (2001). “Kinetic analysis of cytokine gene expression in patients with GVHD after donor lymphocyte infusion.” Bone Marrow Transplant 27(4): 373-80.
Daubener, W. et al. (1995). “Establishment of T-helper type 1- and T-helper type 2-like human Toxoplasma antigen-specific T-cell clones.” Immunology, vol. 86, No. 1: pp. 79-84.
Deeths, M. J. et al. (1999). “CD8+ T Cells Become Nonresponsive (Anergic) Following Activation in the Presence of Costimulation.” The Journal of Immunology, vol. 163, No. 1: pp. 102-110.
De Vita, F., M. Orditura, et al. (2000). “Serum interleukin-10 is an independent prognostic factor in advanced solid tumors.” Oncol Rep 7(2): 357-61.
de Waal Malefyt, R. et al. (1993). “Direct Effects of IL-10 on Subsets of Human CD4+ T Cell Clones and Resting T Cells. Specific Inhibition of IL-2 Production and Proliferation.” The Journal of Im
Belyavskyi Michail A
Immunovative Therapies Ltd.
Sawicki Z. Peter
Westman Champlin & Kelly P.A.
LandOfFree
Device for enhancing immunostimulatory capabilities of T-cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Device for enhancing immunostimulatory capabilities of T-cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Device for enhancing immunostimulatory capabilities of T-cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675584